Stocks
ОЗОН Фармацевтика Financial Statements (OZPH) |
||||||||
| ОЗОН Фармацевтикаsmart-lab.ru | % | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|
| Report date | 11.10.2024 | 11.10.2024 | 11.10.2024 | 11.10.2024 | ||||
| Currency | RUB | RUB | RUB | RUB | ||||
| Financial report URL | ||||||||
| Revenue, bln rub | ? | 17.7 | 19.0 | 19.7 | 24.6 | |||
| Operating Income, bln rub | 5.44 | 5.50 | 6.15 | 9.23 | ||||
| EBITDA, bln rub | ? | 6.04 | 7.19 | 7.54 | 10.2 | |||
| Net profit, bln rub | ? | 3.95 | 3.65 | 4.00 | 6.22 | |||
| OCF, bln rub | ? | 2.77 | -0.994 | 4.66 | 7.60 | |||
| CAPEX, bln rub | ? | 1.19 | 0.682 | 0.706 | 1.96 | |||
| FCF, bln rub | ? | 1.26 | -1.72 | 3.83 | 5.63 | |||
| Ordinary share dividend yield, % | 0.0% | 0.0% | 0.0% | 0.0% | ||||
| Dividend payout ratio, % | 0% | 0% | 0% | 0% | ||||
| OPEX, bln rub | 3.44 | 2.28 | 2.40 | 2.57 | ||||
| Cost of production, bln rub | 8.86 | 9.48 | 10.8 | 12.4 | ||||
| Amortization, bln rub | 0.6 | 0.7 | 0.9 | 1.0 | ||||
| R&D, bln rub | 0.217 | |||||||
| Employment expenses, bln rub | 2.08 | 2.42 | 2.76 | |||||
| Interest expenses, bln rub | 0.570 | 1.000 | 0.883 | 1.24 | ||||
| Assets, bln rub | 29.7 | 34.1 | 34.1 | 38.4 | ||||
| Net Assets, bln rub | ? | 12.8 | 14.7 | 17.1 | 22.4 | |||
| Debt, bln rub | 7.91 | 11.4 | 9.26 | 10.5 | ||||
| Cash, bln rub | 1.37 | 1.11 | 0.950 | 2.69 | ||||
| Net debt, bln rub | 6.53 | 10.3 | 8.31 | 7.86 | ||||
| Ordinary share price, rub | 35.0 | 35.0 | 35.0 | 35.0 | ||||
| Number of ordinary shares, mln | 1 000 | 1 000 | 1 000 | 1 100 | ||||
| Market cap, bln rub | 35.0 | 35.0 | 35.0 | 38.5 | ||||
| EV, bln rub | ? | 41.5 | 45.3 | 43.3 | 46.4 | |||
| Book value, bln rub | 12.7 | 14.4 | 16.8 | 17.2 | ||||
| EPS, rub | ? | 3.95 | 3.65 | 4.00 | 5.65 | |||
| FCF/share, rub | 1.26 | -1.72 | 3.83 | 5.12 | ||||
| BV/share, rub | 12.7 | 14.4 | 16.8 | 15.6 | ||||
| EBITDA margin, % | ? | 34.2% | 37.9% | 38.2% | 41.6% | |||
| Net margin, % | ? | 22.4% | 19.3% | 20.3% | 25.3% | |||
| FCF yield, % | ? | 3.6% | -4.9% | 10.9% | 14.6% | |||
| ROE, % | ? | 30.8% | 24.9% | 23.4% | 27.8% | |||
| ROA, % | ? | 13.3% | 10.7% | 11.7% | 16.2% | |||
| P/E | ? | 8.87 | 9.58 | 8.74 | 6.19 | |||
| P/FCF | 27.7 | -20.4 | 9.14 | 6.84 | ||||
| P/S | ? | 1.98 | 1.85 | 1.77 | 1.57 | |||
| P/BV | ? | 2.76 | 2.42 | 2.08 | 2.24 | |||
| EV/EBITDA | ? | 6.88 | 6.29 | 5.75 | 4.54 | |||
| Debt/EBITDA | 1.08 | 1.43 | 1.10 | 0.77 | ||||
| Employees, people | 1 958 | 2 112 | 1 982 | |||||
| Labour productivity, mln rub/person/year | 9.01 | 8.98 | 9.95 | |||||
| Expenses per employee, thousand rub | 1 060 | 1 145 | 1 391 | |||||
| R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | 11.07% | ||||
| CAPEX/Revenue, % | 7% | 4% | 4% | 8% | ||||
| ОЗОН Фармацевтика shareholders | ||||||||
